US biotech takes the rights in kidney diseases collaboration

20 December 2016

Japanese drugmaker Teijin Pharma (TYO: 3401) has granted the US biotech major Amgen (Nasdaq: AMGN) an exclusive license to compounds discovered or developed during a newly-announced collaborative research in nephrology.

The license to develop and commercialize the therapeutic agents for kidney diseases and disorders resulting from the collaboration covers everywhere in the world outside Japan. Teijin will also have the right to co-promote potential products in select Asian markets.

Teijin, which will receive an undisclosed upfront payment in addition to potential milestones and royalties, sees nephrology as an area of significant unmet need and is confident that the collaboration will yield new treatment options.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK